The addition of IgM and IgA components to IVIG preparations extends the repertoire of immunoglobulins and opens promising opportunities, the first being the possibility to treat patients with IgM or IgA deficiencies and the second being the beneficial properties and functions of IgM and IgA in comparison to IgG [17,18,19]. This evidence concerns the gene CD40LG and hyperinsulinemic hypoglycemia, familial, 4.